WVE
Wave Life Sciences Ltd.
Biotechnology
Market Cap$1.12B
5Y Perf.-43.6%
Build Your Comparison
Side-by-side financial analysisWVE
ARWR
JPM
Try popular comparisons:
Stock Comparison
WVE vs ARWR vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
ARWR
Arrowhead Pharmaceuticals, Inc.
Biotechnology
Market Cap$10.48B
5Y Perf.+72.5%
JPM
JPMorgan Chase & Co.
Banks - Diversified
Market Cap$875.80B
5Y Perf.+241.0%
WVE vs ARWR vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  WVE |  ARWR |  JPM |
|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Banks - Diversified |
| Market Cap | $1.12B | $10.48B | $875.80B |
| Revenue (TTM) | $72M | $622M | $280.33B |
| Net Income (TTM) | $-184M | $-301M | $57.05B |
| Gross Margin | 93.8% | 99.0% | 60.0% |
| Operating Margin | -274.2% | -35.7% | 25.9% |
| Forward P/E | — | — | 14.1x |
| Total Debt | $18M | $366M | $942.38B |
| Cash & Equiv. | $602M | $227M | $343.34B |
WVE vs ARWR vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
WVE
ARWR
JPM
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Wave Life Sciences … (WVE) | 100 | 56.4 | -43.6% |
| Arrowhead Pharmaceu… (ARWR) | 100 | 172.5 | +72.5% |
| JPMorgan Chase & Co. (JPM) | 100 | 341.0 | +241.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: WVE vs ARWR vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: JPM leads in 5 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Arrowhead Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇JPM emerged as the overall leader. Track its performance:
WVE
Wave Life Sciences Ltd.
The Defensive Pick
WVE is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.82, Low D/E 3.4%, current ratio 6.47x
Best for: sleep-well-at-night
ARWR
Arrowhead Pharmaceuticals, Inc.
The Growth Play
ARWR is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 232.6%, EPS growth 99.8%, 3Y rev CAGR 50.5%
- 11.7% 10Y total return vs JPM's 454.4%
- 232.6% revenue growth vs WVE's -60.5%
Best for: growth exposure and long-term compounding
JPM
JPMorgan Chase & Co.
The Banking Pick
JPM carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 15 yrs, beta 0.95, yield 1.9%
- Beta 0.95, yield 1.9%, current ratio 0.52x
- Better valuation composite
Best for: income & stability and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  ARWR | 232.6% revenue growth vs WVE's -60.5% |
| Value |  JPM | Better valuation composite |
| Quality / Margins | JPM | 20.4% margin vs WVE's -255.7% |
| Stability / Safety | JPM | Beta 0.95 vs WVE's 1.82 |
| Dividends | JPM | 1.9% yield; 15-year raise streak; the other 2 pay no meaningful dividend |
| Momentum (1Y) | ARWR | +344.5% vs WVE's -19.2% |
| Efficiency (ROA) | JPM | 1.3% ROA vs WVE's -42.8% |
WVE vs ARWR vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
FY 2025
WVE vs ARWR vs JPM — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLJPMLAGGINGARWR
ARWRArrowhead Pharmaceuti…
0leads
WVEWave Life Sciences Lt…
0leads
JPMJPMorgan Chase & Co.
4leads
6 Total Categories
CATEGORYLEADERvs WVEvs ARWRMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
JPM3/6
Valuation MetricsMultiples, price ratios, and targets
JPM3/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
JPM4/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
JPM2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 3904.5x WVE's $72M. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to WVE's -2.6%. On growth, WVE holds the edge at +3.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric |  WVEWave Life Science… | ARWRArrowhead Pharmac… | JPMJPMorgan Chase & … |
|---|---|---|---|
| RevenueTrailing 12 months | $72M | $622M | $280.3B |
| EBITDAEarnings before interest/tax | -$188M | -$197M | $81.4B |
| Net IncomeAfter-tax profit | -$184M | -$301M | $57.0B |
| Free Cash FlowCash after capex | -$183M | -$51M | $100.9B |
| Gross MarginGross profit ÷ Revenue | +93.8% | +99.0% | +60.0% |
| Operating MarginEBIT ÷ Revenue | -2.7% | -35.7% | +25.9% |
| Net MarginNet income ÷ Revenue | -2.6% | -48.4% | +20.4% |
| FCF MarginFCF ÷ Revenue | -2.6% | -8.2% | +36.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.2% | -86.4% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +55.2% | -133.8% | +16.0% |
JPM leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
JPM leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, JPM's 18.1x EV/EBITDA is more attractive than ARWR's 86.9x.
| Metric | WVEWave Life Science… | ARWRArrowhead Pharmac… | JPMJPMorgan Chase & … |
|---|---|---|---|
| Market CapShares × price | $1.1B | $10.5B | $875.8B |
| Enterprise ValueMkt cap + debt − cash | $533M | $10.6B | $1.47T |
| Trailing P/EPrice ÷ TTM EPS | -4.80x | -6099.18x | 15.64x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 14.08x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 1.20x |
| EV / EBITDAEnterprise value multiple | — | 86.86x | 18.11x |
| Price / SalesMarket cap ÷ Revenue | 26.16x | 12.64x | 3.13x |
| Price / BookPrice ÷ Book value/share | 1.86x | 19.77x | 2.42x |
| Price / FCFMarket cap ÷ FCF | — | 66.81x | 8.68x |
JPM leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
JPM leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-56 for WVE. WVE carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), ARWR scores 6/9 vs WVE's 3/9, reflecting solid financial health.
| Metric | WVEWave Life Science… | ARWRArrowhead Pharmac… | JPMJPMorgan Chase & … |
|---|---|---|---|
| ROE (TTM)Return on equity | -56.4% | -55.1% | +15.9% |
| ROA (TTM)Return on assets | -42.8% | -18.1% | +1.3% |
| ROICReturn on invested capital | — | +9.3% | +4.5% |
| ROCEReturn on capital employed | -54.9% | +8.8% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.03x | 0.73x | 2.60x |
| Net DebtTotal debt minus cash | -$584M | $140M | $599.0B |
| Cash & Equiv.Liquid assets | $602M | $227M | $343.3B |
| Total DebtShort + long-term debt | $18M | $366M | $942.4B |
| Interest CoverageEBIT ÷ Interest expense | — | -2.03x | 0.74x |
JPM leads this category, winning 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — ARWR and JPM each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $20,999 today (with dividends reinvested), compared to $8,025 for WVE. Over the past 12 months, ARWR leads with a +344.5% total return vs WVE's -19.2%. The 3-year compound annual growth rate (CAGR) favors JPM at 32.6% vs WVE's 11.6% — a key indicator of consistent wealth creation.
| Metric | WVEWave Life Science… | ARWRArrowhead Pharmac… | JPMJPMorgan Chase & … |
|---|---|---|---|
| YTD ReturnYear-to-date | -63.6% | +9.8% | -2.8% |
| 1-Year ReturnPast 12 months | -19.2% | +344.5% | +19.1% |
| 3-Year ReturnCumulative with dividends | +39.0% | +110.3% | +133.1% |
| 5-Year ReturnCumulative with dividends | -19.8% | -16.1% | +110.0% |
| 10-Year ReturnCumulative with dividends | -62.8% | +1167.6% | +454.4% |
| CAGR (3Y)Annualised 3-year return | +11.6% | +28.1% | +32.6% |
Evenly matched — ARWR and JPM each lead in 3 of 6 comparable metrics.
Risk & Volatility
JPM leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
JPM is the less volatile stock with a 0.95 beta — it tends to amplify market swings less than WVE's 1.82 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 93.0% from its 52-week high vs WVE's 26.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | WVEWave Life Science… | ARWRArrowhead Pharmac… | JPMJPMorgan Chase & … |
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.76x | 1.69x | 0.94x |
| 52-Week HighHighest price in past year | $21.73 | $82.00 | $337.25 |
| 52-Week LowLowest price in past year | $5.02 | $14.30 | $262.71 |
| % of 52W HighCurrent price vs 52-week peak | +26.7% | +90.7% | +93.0% |
| RSI (14)Momentum oscillator 0–100 | 34.2 | 43.4 | 54.8 |
| Avg Volume (50D)Average daily shares traded | 3.7M | 1.6M | 7.0M |
JPM leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: WVE as "Buy", ARWR as "Buy", JPM as "Buy". Consensus price targets imply 294.0% upside for WVE (target: $23) vs 8.1% for JPM (target: $339). JPM is the only dividend payer here at 1.90% yield — a key consideration for income-focused portfolios.
| Metric | WVEWave Life Science… | ARWRArrowhead Pharmac… | JPMJPMorgan Chase & … |
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $22.89 | $84.00 | $338.78 |
| # AnalystsCovering analysts | 25 | 20 | 61 |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.9% |
| Dividend StreakConsecutive years of raises | — | — | 15 |
| Dividend / ShareAnnual DPS | — | — | $5.95 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +3.9% |
Insufficient data to determine a leader in this category.
Key Takeaway
JPM leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallJPMorgan Chase & Co. (JPM)Leads 4 of 6 categories
Loading custom metrics...
WVE vs ARWR vs JPM: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is WVE or ARWR or JPM a better buy right now?
For growth investors, Arrowhead Pharmaceuticals, Inc.
(ARWR) is the stronger pick with 232. 6% revenue growth year-over-year, versus -60. 5% for Wave Life Sciences Ltd. (WVE). JPMorgan Chase & Co. (JPM) offers the better valuation at 15. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Wave Life Sciences Ltd. (WVE) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — WVE or ARWR or JPM?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +110. 0%, compared to -19. 8% for Wave Life Sciences Ltd. (WVE). Over 10 years, the gap is even starker: ARWR returned +1170% versus WVE's -62. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — WVE or ARWR or JPM?
By beta (market sensitivity over 5 years), JPMorgan Chase & Co.
(JPM) is the lower-risk stock at 0. 94β versus Wave Life Sciences Ltd. 's 1. 76β — meaning WVE is approximately 87% more volatile than JPM relative to the S&P 500. On balance sheet safety, Wave Life Sciences Ltd. (WVE) carries a lower debt/equity ratio of 3% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
04Which is growing faster — WVE or ARWR or JPM?
By revenue growth (latest reported year), Arrowhead Pharmaceuticals, Inc.
(ARWR) is pulling ahead at 232. 6% versus -60. 5% for Wave Life Sciences Ltd. (WVE). On earnings-per-share growth, the picture is similar: Arrowhead Pharmaceuticals, Inc. grew EPS 99. 8% year-over-year, compared to -72. 9% for Wave Life Sciences Ltd.. Over a 3-year CAGR, WVE leads at 127. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — WVE or ARWR or JPM?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus -478. 3% for Wave Life Sciences Ltd. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -504. 1% for WVE. At the gross margin level — before operating expenses — ARWR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is WVE or ARWR or JPM more undervalued right now?
Analyst consensus price targets imply the most upside for WVE: 294.
0% to $22. 89.
07Which pays a better dividend — WVE or ARWR or JPM?
In this comparison, JPM (1.
9% yield) pays a dividend. WVE, ARWR do not pay a meaningful dividend and should not be held primarily for income.
08Is WVE or ARWR or JPM better for a retirement portfolio?
For long-horizon retirement investors, JPMorgan Chase & Co.
(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Wave Life Sciences Ltd. (WVE) carries a higher beta of 1. 76 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, WVE: -62. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between WVE and ARWR and JPM?
These companies operate in different sectors (WVE (Healthcare) and ARWR (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: WVE is a small-cap quality compounder stock; ARWR is a mid-cap high-growth stock; JPM is a large-cap deep-value stock. JPM pays a dividend while WVE, ARWR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.